Market Executive Summary
HIV Therapy involves taking a combination of HIV medicines. HIV Therapy is recommended for everyone who has HIV. HIV Therapy cannot cure HIV, but HIV medicines help people with HIV live longer, healthier lives.
The global HIV Therapy market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the forecast period 2023-2029.
The global key manufacturers of HIV Therapy include ViiV Healthcare, Gilead Sciences, Inc., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc. and Genentech, Inc., etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of HIV Therapy, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of HIV Therapy by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2029.
The global HIV Therapy market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global HIV Therapy market. These figures have been provided in terms of both revenue and sales for the period 2018-2029. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
By Company
ViiV Healthcare
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
AbbVie Inc.
Genentech, Inc.
Mylan N.V.
By Type
Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others
By Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of HIV Therapy in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of HIV Therapy manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7: Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8: China by company, by type and by application, sales, and revenue for each segment.
Chapter 9: APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HIV Therapy sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Table of Contents
1 Report Overview
1.1 HIV Therapy Definition
1.2 Market by Type
1.2.1 Global HIV Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Integrase Inhibitors
1.2.3 Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
1.2.4 Combination HIV Medicines
1.2.5 Others
1.3 Market Segment by Application
1.3.1 Global HIV Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global HIV Therapy Sales
2.1 Global HIV Therapy Revenue Estimates and Forecasts 2018-2029
2.2 Global HIV Therapy Revenue by Region: 2018 VS 2022 VS 2029
2.3 Global HIV Therapy Revenue by Region
2.3.1 Global HIV Therapy Revenue by Region (2018-2023)
2.3.2 Global HIV Therapy Revenue by Region (2024-2029)
2.4 Global HIV Therapy Sales Quantity Estimates and Forecasts 2018-2029
2.5 Global HIV Therapy Sales Quantity by Region: 2018 VS 2022 VS 2029
2.6 Global HIV Therapy Sales Quantity by Region
2.6.1 Global HIV Therapy Sales Quantity by Region (2018-2023)
2.6.2 Global HIV Therapy Sales Quantity by Region (2024-2029)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global HIV Therapy Sales Quantity by Manufacturers
3.1.1 Global HIV Therapy Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global HIV Therapy Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by HIV Therapy Sales in 2022
3.2 Global HIV Therapy Revenue by Manufacturers
3.2.1 Global HIV Therapy Revenue by Manufacturers (2018-2023)
3.2.2 Global HIV Therapy Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by HIV Therapy Revenue in 2022
3.3 Global HIV Therapy Sales Price by Manufacturers
3.4 Global Key Players of HIV Therapy, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global HIV Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of HIV Therapy, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of HIV Therapy, Product Offered and Application
3.8 Global Key Manufacturers of HIV Therapy, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global HIV Therapy Sales Quantity by Type
4.1.1 Global HIV Therapy Historical Sales Quantity by Type (2018-2023)
4.1.2 Global HIV Therapy Forecasted Sales Quantity by Type (2024-2029)
4.1.3 Global HIV Therapy Sales Quantity Market Share by Type (2018-2029)
4.2 Global HIV Therapy Revenue by Type
4.2.1 Global HIV Therapy Historical Revenue by Type (2018-2023)
4.2.2 Global HIV Therapy Forecasted Revenue by Type (2024-2029)
4.2.3 Global HIV Therapy Revenue Market Share by Type (2018-2029)
4.3 Global HIV Therapy Price by Type
4.3.1 Global HIV Therapy Price by Type (2018-2023)
4.3.2 Global HIV Therapy Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global HIV Therapy Sales Quantity by Application
5.1.1 Global HIV Therapy Historical Sales Quantity by Application (2018-2023)
5.1.2 Global HIV Therapy Forecasted Sales Quantity by Application (2024-2029)
5.1.3 Global HIV Therapy Sales Quantity Market Share by Application (2018-2029)
5.2 Global HIV Therapy Revenue by Application
5.2.1 Global HIV Therapy Historical Revenue by Application (2018-2023)
5.2.2 Global HIV Therapy Forecasted Revenue by Application (2024-2029)
5.2.3 Global HIV Therapy Revenue Market Share by Application (2018-2029)
5.3 Global HIV Therapy Price by Application
5.3.1 Global HIV Therapy Price by Application (2018-2023)
5.3.2 Global HIV Therapy Price Forecast by Application (2024-2029)
6 North America
6.1 North America HIV Therapy Sales by Company
6.1.1 North America HIV Therapy Revenue by Company (2018-2023)
6.1.2 North America HIV Therapy Sales Quantity by Company (2018-2023)
6.2 North America HIV Therapy Market Size by Type
6.2.1 North America HIV Therapy Sales Quantity by Type (2018-2029)
6.2.2 North America HIV Therapy Revenue by Type (2018-2029)
6.3 North America HIV Therapy Market Size by Application
6.3.1 North America HIV Therapy Sales Quantity by Application (2018-2029)
6.3.2 North America HIV Therapy Revenue by Application (2018-2029)
6.4 North America HIV Therapy Market Size by Country
6.4.1 North America HIV Therapy Revenue by Country: 2018 VS 2022 VS 2029
6.4.2 North America HIV Therapy Revenue by Country (2018-2029)
6.4.3 North America HIV Therapy Sales Quantity by Country (2018-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe HIV Therapy Sales by Company
7.1.1 Europe HIV Therapy Sales Quantity by Company (2018-2023)
7.1.2 Europe HIV Therapy Revenue by Company (2018-2023)
7.2 Europe HIV Therapy Market Size by Type
7.2.1 Europe HIV Therapy Sales Quantity by Type (2018-2029)
7.2.2 Europe HIV Therapy Revenue by Type (2018-2029)
7.3 Europe HIV Therapy Market Size by Application
7.3.1 Europe HIV Therapy Sales Quantity by Application (2018-2029)
7.3.2 Europe HIV Therapy Revenue by Application (2018-2029)
7.4 Europe HIV Therapy Market Size by Country
7.4.1 Europe HIV Therapy Revenue by Country: 2018 VS 2022 VS 2029
7.4.2 Europe HIV Therapy Revenue by Country (2018-2029)
7.4.3 Europe HIV Therapy Sales Quantity by Country (2018-2029)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China HIV Therapy Sales by Company
8.1.1 China HIV Therapy Sales Quantity by Company (2018-2023)
8.1.2 China HIV Therapy Revenue by Company (2018-2023)
8.2 China HIV Therapy Market Size by Type
8.2.1 China HIV Therapy Sales Quantity by Type (2018-2029)
8.2.2 China HIV Therapy Revenue by Type (2018-2029)
8.3 China HIV Therapy Market Size by Application
8.3.1 China HIV Therapy Sales Quantity by Application (2018-2029)
8.3.2 China HIV Therapy Revenue by Application (2018-2029)
9 APAC (excluding China)
9.1 APAC HIV Therapy Sales by Company
9.1.1 APAC HIV Therapy Sales Quantity by Company (2018-2023)
9.1.2 APAC HIV Therapy Revenue by Company (2018-2023)
9.2 APAC HIV Therapy Market Size by Type
9.2.1 APAC HIV Therapy Sales Quantity by Type (2018-2029)
9.2.2 APAC HIV Therapy Revenue by Type (2018-2029)
9.3 APAC HIV Therapy Market Size by Application
9.3.1 APAC HIV Therapy Sales Quantity by Application (2018-2029)
9.3.2 APAC HIV Therapy Revenue by Application (2018-2029)
9.4 APAC HIV Therapy Market Size by Region
9.4.1 APAC HIV Therapy Revenue by Region: 2018 VS 2022 VS 2029
9.4.2 APAC HIV Therapy Revenue by Region (2018-2029)
9.4.3 APAC HIV Therapy Sales Quantity by Region (2018-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America HIV Therapy Sales by Company
10.1.1 Middle East, Africa and Latin America HIV Therapy Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America HIV Therapy Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America HIV Therapy Market Size by Type
10.2.1 Middle East, Africa and Latin America HIV Therapy Sales Quantity by Type (2018-2029)
10.2.2 Middle East, Africa and Latin America HIV Therapy Revenue by Type (2018-2029)
10.3 Middle East, Africa and Latin America HIV Therapy Market Size by Application
10.3.1 Middle East, Africa and Latin America HIV Therapy Sales Quantity by Application (2018-2029)
10.3.2 Middle East, Africa and Latin America HIV Therapy Revenue by Application (2018-2029)
10.4 Middle East, Africa and Latin America HIV Therapy Market Size by Country
10.4.1 Middle East, Africa and Latin America HIV Therapy Revenue by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa and Latin America HIV Therapy Revenue by Country (2018-2029)
10.4.3 Middle East, Africa and Latin America HIV Therapy Sales Quantity by Country (2018-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 ViiV Healthcare
11.1.1 ViiV Healthcare Company Information
11.1.2 ViiV Healthcare Overview
11.1.3 ViiV Healthcare HIV Therapy Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 ViiV Healthcare HIV Therapy Products and Services
11.1.5 ViiV Healthcare HIV Therapy SWOT Analysis
11.1.6 ViiV Healthcare Recent Developments
11.2 Gilead Sciences, Inc.
11.2.1 Gilead Sciences, Inc. Company Information
11.2.2 Gilead Sciences, Inc. Overview
11.2.3 Gilead Sciences, Inc. HIV Therapy Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Gilead Sciences, Inc. HIV Therapy Products and Services
11.2.5 Gilead Sciences, Inc. HIV Therapy SWOT Analysis
11.2.6 Gilead Sciences, Inc. Recent Developments
11.3 GlaxoSmithKline Plc
11.3.1 GlaxoSmithKline Plc Company Information
11.3.2 GlaxoSmithKline Plc Overview
11.3.3 GlaxoSmithKline Plc HIV Therapy Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 GlaxoSmithKline Plc HIV Therapy Products and Services
11.3.5 GlaxoSmithKline Plc HIV Therapy SWOT Analysis
11.3.6 GlaxoSmithKline Plc Recent Developments
11.4 Merck Sharp & Dohme Corp.
11.4.1 Merck Sharp & Dohme Corp. Company Information
11.4.2 Merck Sharp & Dohme Corp. Overview
11.4.3 Merck Sharp & Dohme Corp. HIV Therapy Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Merck Sharp & Dohme Corp. HIV Therapy Products and Services
11.4.5 Merck Sharp & Dohme Corp. HIV Therapy SWOT Analysis
11.4.6 Merck Sharp & Dohme Corp. Recent Developments
11.5 Bristol-Myers Squibb Company
11.5.1 Bristol-Myers Squibb Company Company Information
11.5.2 Bristol-Myers Squibb Company Overview
11.5.3 Bristol-Myers Squibb Company HIV Therapy Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Bristol-Myers Squibb Company HIV Therapy Products and Services
11.5.5 Bristol-Myers Squibb Company HIV Therapy SWOT Analysis
11.5.6 Bristol-Myers Squibb Company Recent Developments
11.6 Janssen Pharmaceuticals, Inc.
11.6.1 Janssen Pharmaceuticals, Inc. Company Information
11.6.2 Janssen Pharmaceuticals, Inc. Overview
11.6.3 Janssen Pharmaceuticals, Inc. HIV Therapy Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Janssen Pharmaceuticals, Inc. HIV Therapy Products and Services
11.6.5 Janssen Pharmaceuticals, Inc. HIV Therapy SWOT Analysis
11.6.6 Janssen Pharmaceuticals, Inc. Recent Developments
11.7 Boehringer Ingelheim International GmbH
11.7.1 Boehringer Ingelheim International GmbH Company Information
11.7.2 Boehringer Ingelheim International GmbH Overview
11.7.3 Boehringer Ingelheim International GmbH HIV Therapy Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Boehringer Ingelheim International GmbH HIV Therapy Products and Services
11.7.5 Boehringer Ingelheim International GmbH HIV Therapy SWOT Analysis
11.7.6 Boehringer Ingelheim International GmbH Recent Developments
11.8 AbbVie Inc.
11.8.1 AbbVie Inc. Company Information
11.8.2 AbbVie Inc. Overview
11.8.3 AbbVie Inc. HIV Therapy Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 AbbVie Inc. HIV Therapy Products and Services
11.8.5 AbbVie Inc. HIV Therapy SWOT Analysis
11.8.6 AbbVie Inc. Recent Developments
11.9 Genentech, Inc.
11.9.1 Genentech, Inc. Company Information
11.9.2 Genentech, Inc. Overview
11.9.3 Genentech, Inc. HIV Therapy Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Genentech, Inc. HIV Therapy Products and Services
11.9.5 Genentech, Inc. HIV Therapy SWOT Analysis
11.9.6 Genentech, Inc. Recent Developments
11.10 Mylan N.V.
11.10.1 Mylan N.V. Company Information
11.10.2 Mylan N.V. Overview
11.10.3 Mylan N.V. HIV Therapy Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Mylan N.V. HIV Therapy Products and Services
11.10.5 Mylan N.V. HIV Therapy SWOT Analysis
11.10.6 Mylan N.V. Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 HIV Therapy Value Chain Analysis
12.2 HIV Therapy Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 HIV Therapy Production Mode & Process
12.4 HIV Therapy Sales and Marketing
12.4.1 HIV Therapy Sales Channels
12.4.2 HIV Therapy Distributors
12.5 HIV Therapy Customers
13 Market Dynamics
13.1 HIV Therapy Industry Trends
13.2 HIV Therapy Market Drivers
13.3 HIV Therapy Market Challenges
13.4 HIV Therapy Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Figures
List of Tables
Table 1. Global HIV Therapy Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Integrase Inhibitors
Table 3. Major Manufacturers of Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Table 4. Major Manufacturers of Combination HIV Medicines
Table 5. Major Manufacturers of Others
Table 6. Global HIV Therapy Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global HIV Therapy Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global HIV Therapy Revenue by Region (2018-2023) & (US$ Million)
Table 9. Global HIV Therapy Revenue Market Share by Region (2018-2023)
Table 10. Global HIV Therapy Revenue by Region (2024-2029) & (US$ Million)
Table 11. Global HIV Therapy Revenue Market Share by Region (2024-2029)
Table 12. Global HIV Therapy Sales Quantity by Region: 2018 VS 2022 VS 2029 (K Units)
Table 13. Global HIV Therapy Sales by Region (2018-2023) & (K Units)
Table 14. Global HIV Therapy Sales Market Share by Region (2018-2023)
Table 15. Global HIV Therapy Sales by Region (2024-2029) & (K Units)
Table 16. Global HIV Therapy Sales Market Share by Region (2024-2029)
Table 17. Global HIV Therapy Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 18. Global HIV Therapy Sales Quantity Share by Manufacturers (2018-2023)
Table 19. Global HIV Therapy Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 20. Global HIV Therapy Revenue Share by Manufacturers (2018-2023)
Table 21. Global HIV Therapy Price by Manufacturers 2018-2023 (US$/Unit)
Table 22. Global Key Players of HIV Therapy, Industry Ranking, 2021 VS 2022
Table 23. Global HIV Therapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global HIV Therapy by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HIV Therapy as of 2022)
Table 25. Global Key Manufacturers of HIV Therapy, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of HIV Therapy, Product Offered and Application
Table 27. Global Key Manufacturers of HIV Therapy, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global HIV Therapy Sales Quantity by Type (2018-2023) & (K Units)
Table 30. Global HIV Therapy Sales Quantity by Type (2024-2029) & (K Units)
Table 31. Global HIV Therapy Sales Quantity Share by Type (2018-2023)
Table 32. Global HIV Therapy Sales Quantity Share by Type (2024-2029)
Table 33. Global HIV Therapy Revenue by Type (2018-2023) & (US$ Million)
Table 34. Global HIV Therapy Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global HIV Therapy Revenue Share by Type (2018-2023)
Table 36. Global HIV Therapy Revenue Share by Type (2024-2029)
Table 37. HIV Therapy Price by Type (2018-2023) & (US$/Unit)
Table 38. Global HIV Therapy Price Forecast by Type (2024-2029) & (US$/Unit)
Table 39. Global HIV Therapy Sales Quantity by Application (2018-2023) & (K Units)
Table 40. Global HIV Therapy Sales Quantity by Application (2024-2029) & (K Units)
Table 41. Global HIV Therapy Sales Quantity Share by Application (2018-2023)
Table 42. Global HIV Therapy Sales Quantity Share by Application (2024-2029)
Table 43. Global HIV Therapy Revenue by Application (2018-2023) & (US$ Million)
Table 44. Global HIV Therapy Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global HIV Therapy Revenue Share by Application (2018-2023)
Table 46. Global HIV Therapy Revenue Share by Application (2024-2029)
Table 47. HIV Therapy Price by Application (2018-2023) & (US$/Unit)
Table 48. Global HIV Therapy Price Forecast by Application (2024-2029) & (US$/Unit)
Table 49. North America HIV Therapy Revenue by Company (2018-2023) & (US$ Million)
Table 50. North America HIV Therapy Sales Quantity by Company (2018-2023) & (K Units)
Table 51. North America HIV Therapy Sales Quantity by Type (2018-2023) & (K Units)
Table 52. North America HIV Therapy Sales Quantity by Type (2024-2029) & (K Units)
Table 53. North America HIV Therapy Revenue by Type (2018-2023) & (US$ Million)
Table 54. North America HIV Therapy Revenue by Type (2024-2029) & (US$ Million)
Table 55. North America HIV Therapy Sales Quantity by Application (2018-2023) & (K Units)
Table 56. North America HIV Therapy Sales Quantity by Application (2024-2029) & (K Units)
Table 57. North America HIV Therapy Revenue by Application (2018-2023) & (US$ Million)
Table 58. North America HIV Therapy Revenue by Application (2024-2029) & (US$ Million)
Table 59. North America HIV Therapy Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 60. North America HIV Therapy Revenue by Country (2018-2023) & (US$ Million)
Table 61. North America HIV Therapy Revenue by Country (2024-2029) & (US$ Million)
Table 62. North America HIV Therapy Sales Quantity by Country (2018-2023) & (K Units)
Table 63. North America HIV Therapy Sales Quantity by Country (2024-2029) & (K Units)
Table 64. Europe HIV Therapy Sales Quantity by Company (2018-2023) & (K Units)
Table 65. Europe HIV Therapy Revenue by Company (2018-2023) & (US$ Million)
Table 66. Europe HIV Therapy Sales Quantity by Type (2018-2023) & (K Units)
Table 67. Europe HIV Therapy Sales Quantity by Type (2024-2029) & (K Units)
Table 68. Europe HIV Therapy Revenue by Type (2018-2023) & (US$ Million)
Table 69. Europe HIV Therapy Revenue by Type (2024-2029) & (US$ Million)
Table 70. Europe HIV Therapy Sales Quantity by Application (2018-2023) & (K Units)
Table 71. Europe HIV Therapy Sales Quantity by Application (2024-2029) & (K Units)
Table 72. Europe HIV Therapy Revenue by Application (2018-2023) & (US$ Million)
Table 73. Europe HIV Therapy Revenue by Application (2024-2029) & (US$ Million)
Table 74. Europe HIV Therapy Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 75. Europe HIV Therapy Revenue by Country (2018-2023) & (US$ Million)
Table 76. Europe HIV Therapy Revenue by Country (2024-2029) & (US$ Million)
Table 77. Europe HIV Therapy Sales Quantity by Country (2018-2023) & (K Units)
Table 78. Europe HIV Therapy Sales Quantity by Country (2024-2029) & (K Units)
Table 79. China HIV Therapy Sales Quantity by Company (2018-2023) & (K Units)
Table 80. China HIV Therapy Revenue by Company (2018-2023) & (US$ Million)
Table 81. China HIV Therapy Sales Quantity by Type (2018-2023) & (K Units)
Table 82. China HIV Therapy Sales Quantity by Type (2024-2029) & (K Units)
Table 83. China HIV Therapy Revenue by Type (2018-2023) & (US$ Million)
Table 84. China HIV Therapy Revenue by Type (2024-2029) & (US$ Million)
Table 85. China HIV Therapy Sales Quantity by Application (2018-2023) & (K Units)
Table 86. China HIV Therapy Sales Quantity by Application (2024-2029) & (K Units)
Table 87. China HIV Therapy Revenue by Application (2018-2023) & (US$ Million)
Table 88. China HIV Therapy Revenue by Application (2024-2029) & (US$ Million)
Table 89. APAC HIV Therapy Sales Quantity by Company (2018-2023) & (K Units)
Table 90. APAC HIV Therapy Revenue by Company (2018-2023) & (US$ Million)
Table 91. APAC HIV Therapy Sales Quantity by Type (2018-2023) & (K Units)
Table 92. APAC HIV Therapy Sales Quantity by Type (2024-2029) & (K Units)
Table 93. APAC HIV Therapy Revenue by Type (2018-2023) & (US$ Million)
Table 94. APAC HIV Therapy Revenue by Type (2024-2029) & (US$ Million)
Table 95. APAC HIV Therapy Sales Quantity by Application (2018-2023) & (K Units)
Table 96. APAC HIV Therapy Sales Quantity by Application (2024-2029) & (K Units)
Table 97. APAC HIV Therapy Revenue by Application (2018-2023) & (US$ Million)
Table 98. APAC HIV Therapy Revenue by Application (2024-2029) & (US$ Million)
Table 99. APAC HIV Therapy Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 100. APAC HIV Therapy Revenue by Region (2018-2023) & (US$ Million)
Table 101. APAC HIV Therapy Revenue by Region (2024-2029) & (US$ Million)
Table 102. APAC HIV Therapy Sales Quantity by Region (2018-2023) & (K Units)
Table 103. APAC HIV Therapy Sales Quantity by Region (2024-2029) & (K Units)
Table 104. Middle East, Africa and Latin America HIV Therapy Sales Quantity by Company (2018-2023) & (K Units)
Table 105. Middle East, Africa and Latin America HIV Therapy Revenue by Company (2018-2023) & (US$ Million)
Table 106. Middle East, Africa and Latin America HIV Therapy Sales Quantity by Type (2018-2023) & (K Units)
Table 107. Middle East, Africa and Latin America HIV Therapy Sales Quantity by Type (2024-2029) & (K Units)
Table 108. Middle East, Africa and Latin America HIV Therapy Revenue by Type (2018-2023) & (US$ Million)
Table 109. Middle East, Africa and Latin America HIV Therapy Revenue by Type (2024-2029) & (US$ Million)
Table 110. Middle East, Africa and Latin America HIV Therapy Sales Quantity by Application (2018-2023) & (K Units)
Table 111. Middle East, Africa and Latin America HIV Therapy Sales Quantity by Application (2024-2029) & (K Units)
Table 112. Middle East, Africa and Latin America HIV Therapy Revenue by Application (2018-2023) & (US$ Million)
Table 113. Middle East, Africa and Latin America HIV Therapy Revenue by Application (2024-2029) & (US$ Million)
Table 114. Middle East, Africa and Latin America HIV Therapy Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 115. Middle East, Africa and Latin America HIV Therapy Revenue by Country (2018-2023) & (US$ Million)
Table 116. Middle East, Africa and Latin America HIV Therapy Revenue by Country (2024-2029) & (US$ Million)
Table 117. Middle East, Africa and Latin America HIV Therapy Sales Quantity by Country (2018-2023) & (K Units)
Table 118. Middle East, Africa and Latin America HIV Therapy Sales Quantity by Country (2024-2029) & (K Units)
Table 119. ViiV Healthcare Company Information
Table 120. ViiV Healthcare Description and Overview
Table 121. ViiV Healthcare HIV Therapy Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 122. ViiV Healthcare HIV Therapy Product and Services
Table 123. ViiV Healthcare HIV Therapy SWOT Analysis
Table 124. ViiV Healthcare Recent Developments
Table 125. Gilead Sciences, Inc. Company Information
Table 126. Gilead Sciences, Inc. Description and Overview
Table 127. Gilead Sciences, Inc. HIV Therapy Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 128. Gilead Sciences, Inc. HIV Therapy Product and Services
Table 129. Gilead Sciences, Inc. HIV Therapy SWOT Analysis
Table 130. Gilead Sciences, Inc. Recent Developments
Table 131. GlaxoSmithKline Plc Company Information
Table 132. GlaxoSmithKline Plc Description and Overview
Table 133. GlaxoSmithKline Plc HIV Therapy Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 134. GlaxoSmithKline Plc HIV Therapy Product and Services
Table 135. GlaxoSmithKline Plc HIV Therapy SWOT Analysis
Table 136. GlaxoSmithKline Plc Recent Developments
Table 137. Merck Sharp & Dohme Corp. Company Information
Table 138. Merck Sharp & Dohme Corp. Description and Overview
Table 139. Merck Sharp & Dohme Corp. HIV Therapy Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 140. Merck Sharp & Dohme Corp. HIV Therapy Product and Services
Table 141. Merck Sharp & Dohme Corp. HIV Therapy SWOT Analysis
Table 142. Merck Sharp & Dohme Corp. Recent Developments
Table 143. Bristol-Myers Squibb Company Company Information
Table 144. Bristol-Myers Squibb Company Description and Overview
Table 145. Bristol-Myers Squibb Company HIV Therapy Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 146. Bristol-Myers Squibb Company HIV Therapy Product and Services
Table 147. Bristol-Myers Squibb Company HIV Therapy SWOT Analysis
Table 148. Bristol-Myers Squibb Company Recent Developments
Table 149. Janssen Pharmaceuticals, Inc. Company Information
Table 150. Janssen Pharmaceuticals, Inc. Description and Overview
Table 151. Janssen Pharmaceuticals, Inc. HIV Therapy Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 152. Janssen Pharmaceuticals, Inc. HIV Therapy Product and Services
Table 153. Janssen Pharmaceuticals, Inc. HIV Therapy SWOT Analysis
Table 154. Janssen Pharmaceuticals, Inc. Recent Developments
Table 155. Boehringer Ingelheim International GmbH Company Information
Table 156. Boehringer Ingelheim International GmbH Description and Overview
Table 157. Boehringer Ingelheim International GmbH HIV Therapy Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 158. Boehringer Ingelheim International GmbH HIV Therapy Product and Services
Table 159. Boehringer Ingelheim International GmbH HIV Therapy SWOT Analysis
Table 160. Boehringer Ingelheim International GmbH Recent Developments
Table 161. AbbVie Inc. Company Information
Table 162. AbbVie Inc. Description and Overview
Table 163. AbbVie Inc. HIV Therapy Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 164. AbbVie Inc. HIV Therapy Product and Services
Table 165. AbbVie Inc. HIV Therapy SWOT Analysis
Table 166. AbbVie Inc. Recent Developments
Table 167. Genentech, Inc. Company Information
Table 168. Genentech, Inc. Description and Overview
Table 169. Genentech, Inc. HIV Therapy Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 170. Genentech, Inc. HIV Therapy Product and Services
Table 171. Genentech, Inc. HIV Therapy SWOT Analysis
Table 172. Genentech, Inc. Recent Developments
Table 173. Mylan N.V. Company Information
Table 174. Mylan N.V. Description and Overview
Table 175. Mylan N.V. HIV Therapy Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2023)
Table 176. Mylan N.V. HIV Therapy Product and Services
Table 177. Mylan N.V. HIV Therapy SWOT Analysis
Table 178. Mylan N.V. Recent Developments
Table 179. Key Raw Materials Lists
Table 180. Raw Materials Key Suppliers Lists
Table 181. HIV Therapy Distributors List
Table 182. HIV Therapy Customers List
Table 183. HIV Therapy Market Trends
Table 184. HIV Therapy Market Drivers
Table 185. HIV Therapy Market Challenges
Table 186. HIV Therapy Market Restraints
Table 187. Research Programs/Design for This Report
Table 188. Key Data Information from Secondary Sources
Table 189. Key Data Information from Primary Sources
List of Figures
Figure 1. HIV Therapy Product Picture
Figure 2. Global HIV Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global HIV Therapy Market Share by Type in 2022 & 2029
Figure 4. Integrase Inhibitors Product Picture
Figure 5. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Product Picture
Figure 6. Combination HIV Medicines Product Picture
Figure 7. Others Product Picture
Figure 8. Global HIV Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global HIV Therapy Market Share by Application in 2022 & 2029
Figure 10. Hospital Pharmacies
Figure 11. Retail Pharmacies
Figure 12. Online Pharmacies
Figure 13. Others
Figure 14. HIV Therapy Report Years Considered
Figure 15. Global HIV Therapy Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global HIV Therapy Revenue 2018-2029 (US$ Million)
Figure 17. Global HIV Therapy Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 18. Global HIV Therapy Sales Quantity 2018-2029 (K Units)
Figure 19. Global HIV Therapy Sales Quantity Market Share by Region (2018-2023)
Figure 20. Global HIV Therapy Sales Quantity Market Share by Region (2024-2029)
Figure 21. North America HIV Therapy Sales Quantity YoY (2018-2029) & (K Units)
Figure 22. North America HIV Therapy Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Europe HIV Therapy Sales Quantity YoY (2018-2029) & (K Units)
Figure 24. Europe HIV Therapy Revenue YoY (2018-2029) & (US$ Million)
Figure 25. China HIV Therapy Sales Quantity YoY (2018-2029) & (K Units)
Figure 26. China HIV Therapy Revenue YoY (2018-2029) & (US$ Million)
Figure 27. APAC HIV Therapy Sales Quantity YoY (2018-2029) & (K Units)
Figure 28. APAC HIV Therapy Revenue YoY (2018-2029) & (US$ Million)
Figure 29. Middle East, Africa and Latin America HIV Therapy Sales Quantity YoY (2018-2029) & (K Units)
Figure 30. Middle East, Africa and Latin America HIV Therapy Revenue YoY (2018-2029) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by HIV Therapy Sales Quantity in 2022
Figure 32. The Top 10 and Top 5 Players Market Share by HIV Therapy Revenue in 2022
Figure 33. HIV Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global HIV Therapy Sales Quantity Market Share by Type (2018-2029)
Figure 35. Global HIV Therapy Revenue Market Share by Type (2018-2029)
Figure 36. Global HIV Therapy Sales Quantity Market Share by Application (2018-2029)
Figure 37. Global HIV Therapy Revenue Market Share by Application (2018-2029)
Figure 38. North America HIV Therapy Revenue Market Share by Company in 2022
Figure 39. North America HIV Therapy Sales Quantity Market Share by Company in 2022
Figure 40. North America HIV Therapy Sales Quantity Market Share by Type (2018-2029)
Figure 41. North America HIV Therapy Revenue Market Share by Type (2018-2029)
Figure 42. North America HIV Therapy Sales Quantity Market Share by Application (2018-2029)
Figure 43. North America HIV Therapy Revenue Market Share by Application (2018-2029)
Figure 44. North America HIV Therapy Revenue Share by Country (2018-2029)
Figure 45. North America HIV Therapy Sales Quantity Share by Country (2018-2029)
Figure 46. U.S. HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 47. Canada HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 48. Europe HIV Therapy Sales Quantity Market Share by Company in 2022
Figure 49. Europe HIV Therapy Revenue Market Share by Company in 2022
Figure 50. Europe HIV Therapy Sales Quantity Market Share by Type (2018-2029)
Figure 51. Europe HIV Therapy Revenue Market Share by Type (2018-2029)
Figure 52. Europe HIV Therapy Sales Quantity Market Share by Application (2018-2029)
Figure 53. Europe HIV Therapy Revenue Market Share by Application (2018-2029)
Figure 54. Europe HIV Therapy Revenue Share by Country (2018-2029)
Figure 55. Europe HIV Therapy Sales Quantity Share by Country (2018-2029)
Figure 56. Germany HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 57. France HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 58. U.K. HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 59. Italy HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 60. Russia HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 61. China HIV Therapy Sales Quantity Market Share by Company in 2022
Figure 62. China HIV Therapy Revenue Market Share by Company in 2022
Figure 63. China HIV Therapy Sales Quantity Market Share by Type (2018-2029)
Figure 64. China HIV Therapy Revenue Market Share by Type (2018-2029)
Figure 65. China HIV Therapy Sales Quantity Market Share by Application (2018-2029)
Figure 66. China HIV Therapy Revenue Market Share by Application (2018-2029)
Figure 67. APAC HIV Therapy Sales Quantity Market Share by Company in 2022
Figure 68. APAC HIV Therapy Revenue Market Share by Company in 2022
Figure 69. APAC HIV Therapy Sales Quantity Market Share by Type (2018-2029)
Figure 70. APAC HIV Therapy Revenue Market Share by Type (2018-2029)
Figure 71. APAC HIV Therapy Sales Quantity Market Share by Application (2018-2029)
Figure 72. APAC HIV Therapy Revenue Market Share by Application (2018-2029)
Figure 73. APAC HIV Therapy Revenue Share by Region (2018-2029)
Figure 74. APAC HIV Therapy Sales Quantity Share by Region (2018-2029)
Figure 75. Japan HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 76. South Korea HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 77. China Taiwan HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 78. Southeast Asia HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 79. India HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 80. Middle East, Africa and Latin America HIV Therapy Sales Quantity Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America HIV Therapy Revenue Market Share by Company in 2022
Figure 82. Middle East, Africa and Latin America HIV Therapy Sales Quantity Market Share by Type (2018-2029)
Figure 83. Middle East, Africa and Latin America HIV Therapy Revenue Market Share by Type (2018-2029)
Figure 84. Middle East, Africa and Latin America HIV Therapy Sales Quantity Market Share by Application (2018-2029)
Figure 85. Middle East, Africa and Latin America HIV Therapy Revenue Market Share by Application (2018-2029)
Figure 86. Middle East, Africa and Latin America HIV Therapy Sales Quantity Share by Country (2018-2029)
Figure 87. Middle East, Africa and Latin America HIV Therapy Revenue Share by Country (2018-2029)
Figure 88. Brazil HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 89. Mexico HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 90. Turkey HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 91. Israel HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 92. GCC Countries HIV Therapy Revenue (2018-2029) & (US$ Million)
Figure 93. HIV Therapy Value Chain
Figure 94. HIV Therapy Production Process
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Distributors Profiles
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed
This report focuses on:
► Intelligent insights to take informed business decisions.
► Qualitative and quantitative analysis of the market.
► Market size and forecasts from 2024 to 2030.
► Opportunities for expansion and in-depth market analysis.
► Segmentation and regional revenue forecasts.
► Analysis of the market share and competitive landscape.
► Strategic recommendations for future growth.
You'll also receive:
► A comprehensive market research report in PDF or PPT formats.
► Access to our analysts to learn more about the report and get answers to your specific business questions.
► The option to customize the report to meet your specific needs, such as adding more countries or regions or developing abusiness case to launch a new product.
Contact us today to learn more and get sample report.
Our Research Reports Look Like This
